PRO-1286

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NamePRO-1286
Drug Alias NamePRO-1286GEN1286GEN-1286
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Payload > Exatecan payloadBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody drug conjugate (ADC) > Linker > Cleavable linker +[4] 
Mechanisms of ActionAnti-Epidermal growth factor receptor erbB1Anti-Hepatocyte growth factor receptorDNA topoisomerase I inhibitors
TargetsEpidermal growth factor receptor erbB1Hepatocyte growth factor receptorDNA topoisomerase I
Therapy Area/IndicationsSolid tumoursNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesProfoundBio (Suzhou) Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesN/A
Inactive CompaniesProfoundBio (Suzhou) Co LtdGenmab A/S
Active IndicationsN/A
Inactive IndicationsSolid tumoursNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A